Heart failure & cardiomyopathiesCohort study
Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients
- Retrospective cohort study
- registry-based
- nationwide
- propensity-score matched
Authors' conclusion
This nationwide real-world study shows that patients with HF who received GLP-1RA have a significant reduction in CV mortality, which is particularly pronounced in overweight and obese patients with reduced ejection fraction.
Study context
- Population
- Patients with heart failure (HF) and body mass index (BMI) >25 kg/m², Swedish HF Registry since 2007
- Participants
- 808 vs 34,247
- Exposure
- GLP-1RA vs no GLP-1RA
- GLP-1RAn = 808
- No GLP-1RAn = 34,247reference
- Outcome
- Mortality (all-cause and CV)
- Follow-up
- 2 years after index registration
Main finding
As reported in the abstract
All-cause and CV mortality · within 2 years after index registration
GLP-1RA vs No GLP-1RAAdjusted hazard ratio (95% CI)P value
all-cause mortality, overall cohort
0.75(0.60–0.94)
P = 0.013CV mortality, overall cohort
0.52(0.35–0.77)
P = 0.0010all-cause mortality, 1:1 propensity score matched cohort
0.79(0.59–1.06)
P = 0.11CV mortality, 1:1 propensity score matched cohort
0.53(0.32–0.87)
P = 0.012Observational data: associations, not effects.
Further findings
- Diabetes mellitus among GLP-1RA-treated
- 96.3%
Cardiovascular (CV) death, by BMI and EF (subgroups)
- GLP-1RA-associated CV death reduction more pronounced with BMI >30 kg/m² and appears greater with EF ≤40% vs >40%
Original publication
Glucagon-Like Peptide 1 Receptor Agonist Is Associated With Improved Survival in Overweight Heart Failure Patients. JACC Heart Fail. Published 12 March 2025. doi:10.1016/j.jchf.2024.12.004
Summarised from the published abstract; every number is checked against it